RVL Pharmaceuticals Focuses on Scaling Upneeq as Market Momentum Builds
RVL Pharmaceuticals reported 22% revenue growth for Upneeq in Q3 2025 and announced leadership changes to support continued expansion of the product.
RVL Pharmaceuticals reported 22% revenue growth for Upneeq in Q3 2025 and announced leadership changes to support continued expansion of the product.
The device combines tumescent local anesthesia infiltration, power-assisted tissue removal, and aspiration into a single platform.